Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
When would you consider an all-oral regimen for patients with Whipple's disease instead of the typical parenteral treatment with ceftriaxone or meropenem followed by oral TMP/SMX?
Moos V, et al., PMID 39978372
Related Questions
Do you recommend, based on current evidence, avoiding antimotility agents in patients with non-fulminant C. difficile infection who have no evidence of ileus?
Do you avoid Daptomycin use when there is evidence of septic pulmonary emboli?
Do you switch to an alternative agent for C difficile colitis for a patient with suspected infection and positive testing who continues to have >3 watery bowel movements daily despite multiple days of oral vancomycin treatment?
When do you recommend limited or targeted respiratory pathogen testing versus a full respiratory pathogen panel in a patient presenting with URI symptoms?
How might the integration of PET/CT with traditional imaging modalities alter the clinical decision-making process for suspected CIED infections without clear generator pocket involvement?
Do routinely recommend antifungal prophylaxis for non-transplant patients who have been diagnosed and completed treatment for possible/probable pulmonary aspergillosis and who will need varying degrees of ongoing immunosuppression?
Do you routinely transition to PO antibiotics for patients with native joint septic arthritis whom have undergone washout and the organism is not S. aureus?
What infectious differentials should be considered for a patient with intractable erythema nodosum that is non-responsive to acyclovir and steroids?
Would you use daptomycin to consolidate therapy in a patient with polymicrobial VRE and rothia bacteremia?
How do you approach using fecal microbiota therapy for recurrent Clostridioides difficile infection in immunocompromised patients?
